JP Patent

JP2012021029A — １，２−ジヒドロピリジン化合物の結晶

Assigned to Eisai R&D Management Co Ltd · Expires 2012-02-02 · 14y expired

What this patent protects

【課題】３−（２−シアノフェニル）−５−（２−ピリジル）−１−フェニル−１，２−ジヒドロピリジン−２−オンの結晶の提供。【解決手段】粉末Ｘ線回折において、回折角度（２θ±０．２°）８．７°に回折ピークを有する、３−（２−シアノフェニル）−５−（２−ピリジル）−１−フェニル−１，２−ジヒドロピリジン−２−オンの水和物の結晶。【選択図】なし

USPTO Abstract

【課題】３−（２−シアノフェニル）−５−（２−ピリジル）−１−フェニル−１，２−ジヒドロピリジン−２−オンの結晶の提供。【解決手段】粉末Ｘ線回折において、回折角度（２θ±０．２°）８．７°に回折ピークを有する、３−（２−シアノフェニル）−５−（２−ピリジル）−１−フェニル−１，２−ジヒドロピリジン−２−オンの水和物の結晶。【選択図】なし

Drugs covered by this patent

Fycompa (PERAMPANEL) · Catalyst Pharms

Patent Metadata

Patent number: JP2012021029A
Jurisdiction: JP
Classification: —
Expires: 2012-02-02
Drug substance claim: No
Drug product claim: No
Assignee: Eisai R&D Management Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.